Why the study?
Does the duration of postimplantation dual antiplatelet therapy prevent device-related thrombus in patients undergoing left atrial appendage occlusion?
Does the duration of postimplantation dual antiplatelet therapy prevent device-related thrombus in patients undergoing left atrial appendage occlusion?
In a real-world series, device-related thrombus after LAA occlusion was associated with patient and procedural characteristics, but not with the duration of postimplantation dual antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Device-related thrombus risk after left atrial appendage occlusion relates to patient and procedural factors, not dual antiplatelet therapy duration; leaves open optimal regimen in trials.
BACKGROUND: Device-related thrombus (DRT) after left atrial appendage occlusion is a worrisome finding with little knowledge about when to expect it and how to prevent it. This study sought to investigate correlates of DRT after left atrial appendage occlusion, its time of diagnosis, and particularly, association with postimplantation dual antiplatelet therapy duration. METHODS AND CONCLUSIONS: In this real-world series, DRT was observed early, late, and very late after left atrial appendage occlusion. It was related to patient and procedural characteristics but not to postimplantation dual antiplatelet therapy duration.
No takes yet. Share an insight, caveat, or question.
Pracoń et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: